HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of vaccination and the new neuraminidase inhibitor, laninamivir, on influenza infection.

AbstractBACKGROUND:
Evidence of the effectiveness of influenza vaccination in children and elderly adults is limited, although this population has the highest risk for influenza infection.
MATERIALS AND METHODS:
We enrolled 4443 participants, aged 3-97 years, who had influenza-kit-positive results during seasons 2007-12, including 2135 with influenza A, 534 with A/H1N1, and 1643 with influenza B. Eligible subjects completed a questionnaire to identify past influenza infection and vaccination history. For the diagnosis of current influenza infection, subjects were examined, and pharyngeal swabs were collected and tested using the Capilia flu rapid diagnosis kit to confirm influenza infection. An interim analysis was performed using clinician-based surveillance data for the entire four seasons of influenza infection in Japan.
RESULTS:
In 3035 adults aged 14-64 years, administration of the influenza vaccine significantly reduced the frequency of infection (P<0.01) in the 2008 and 2010 seasons, but not in the 2009 and 2011 seasons. Moreover, the vaccine did not reduce the frequency of infection in children (aged <13 years) and older adults (aged >65 years) significantly. Laninamivir, oseltamivir phosphate, zanamivir hydrate, and amantadine hydrochloride were administered to 1381, 2432, 1044, and 100 patients, respectively. They were effective in >97% of patients, with no significant differences being found. Adverse effects were few. However, the recurrence rate of influenza infection after treatment was significantly reduced in patients who received laninamivir compared with that in those who received oseltamivir and zanamivir (P<0.01). The effectiveness of laninamivirdid not decrease.
CONCLUSIONS:
The vaccines administered had limited efficacy in reducing the frequency of influenza infection in young adults. Laninamivir significantly reduced the recurrence of influenza infection when compared with other neuraminidase inhibitors.
AuthorsTakuro Mizuno, Shigeru Mizuno, Tsugiyasu Kanda
JournalPloS one (PLoS One) Vol. 9 Issue 4 Pg. e92601 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID24699254 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antiviral Agents
  • Guanidines
  • Influenza Vaccines
  • Pyrans
  • Sialic Acids
  • laninamivir
  • Neuraminidase
  • Zanamivir
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Female
  • Guanidines
  • Humans
  • Influenza Vaccines (therapeutic use)
  • Influenza, Human (epidemiology, prevention & control, virology)
  • Japan (epidemiology)
  • Male
  • Middle Aged
  • Neuraminidase (antagonists & inhibitors)
  • Orthomyxoviridae (classification, drug effects, enzymology)
  • Pyrans
  • Sialic Acids
  • Vaccination
  • Young Adult
  • Zanamivir (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: